MultiCell Technologies, Inc.
MCET
Rank in Stocks
#34657
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Share Price
$0.000001
Last synced: 2026-11-09
Market Cap
$5.00K
Change (1 day)
-90.00%
Change (1 year)
-90.00%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade MultiCell Technologies, Inc. (MCET)
Category
Healthcare
EPS for MultiCell Technologies, Inc. (MCET)
EPS as of August 2015 TTM: $0.00
According to MultiCell Technologies, Inc.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2014 the company had an EPS of 0.00, equal to its 2013 EPS of 0.00.
EPS history for MultiCell Technologies, Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -83.33% |
| 2014 | 0.00 | -83.33% |
| 2013 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 626,300.00% |
US
|
|
| $-7.07 | -282,900.00% |
US
|
|
| $-5.29 | -211,700.00% |
AU
|
|
| $12.88 | 515,104.00% |
BE
|
|
| $21.56 | 862,300.00% |
NL
|
Questions about MultiCell Technologies, Inc.'s earnings per share (EPS)
What is MultiCell Technologies, Inc.'s earnings per share (EPS)?
MultiCell Technologies, Inc.'s earnings per share (EPS) over the last twelve months is $0.00, as of Aug 2015.
What was MultiCell Technologies, Inc.'s earnings per share (EPS) in 2014?
In 2014, MultiCell Technologies, Inc.'s earnings per share (EPS) was 0.00, compared with 0.00 in 2013.
How does MultiCell Technologies, Inc.'s earnings per share (EPS) compare with similar companies?
MultiCell Technologies, Inc.'s earnings per share (EPS) ($0.00) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.